Arkolith/Insider Trading/LYEL/Form 4

Seely Lynn

President and CEO, DirectorLyell Immunopharma, Inc. (LYEL) · full profile →Form 4 · filed Feb 11, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$10K
Net Open-Market Flow
-$10K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 10, 2026Sell(S)438$23.12$10K82K
Feb 9, 2026Grant(A)20K—$082K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 10, 2026Grant(A)155K—$0155K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001327111-26-000001) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML